Synergy Pharmaceuticals Inc., of New York, said it completed an end-of-phase II meeting with the FDA on lead drug plecanatide, a uroguanylin analogue, for the treatment of irritable bowel syndrome with constipation (IBS-C) and reached agreement with the agency for the pivotal phase III IBS-C program set to start in the fourth quarter.